- ST Pharm presents three posters at CRISPR Medicines 2025, promoting new therapeutic platforms
- To establish and operate CRISPR-related gRNA manufacturing facilities within this year
ST Pharm (President & CEO Mooje Sung) announced that it is participating in CRISPR Medicines 2025, the world’s largest conference dedicated to gene-editing therapeutics, held from April 7 to 11 (local time) in Copenhagen, Denmark. The company is actively promoting its new technologies at the event.
CRISPR Medicines 2025 is a prestigious academic conference where global experts in the CRISPR medicine field gather to discuss the latest developments in gene-editing technology and its clinical applications.
ST Pharm is presenting three posters at the conference:
▲ Leveraging of circular RNA synthesis in CRISPR-based therapeutics ▲Innovations of process development: From oligonucleotides to guide RNA optimization using PAT and modeling ▲ Accelerating cost-efficient xRNA therapeutics research with noble ionizable lipid (STLNP®) and capping reagent (SmartCap®) technologies
Through these presentations, ST Pharm aims to highlight its growing competitiveness in the CRISPR-based therapeutic field.According to recent R&D trends, gene therapies are drawing increasing attention due to their potential to cure diseases by directly modifying the underlying genetic causes. Development of gene therapies is underway for rare genetic diseases, cancer, blood disorders, and ophthalmologic conditions. In particular, advancements in LNP-based delivery technologies and RNA stabilization methods are accelerating progress in this field.
ST Pharm has established automated processes and high-purity production technologies that enable efficient synthesis of various oligonucleotides, including guide RNA (gRNA).
The company’s proprietary STLNP® technology significantly improves delivery efficiency and safety compared to existing LNPs. In addition, the SmartCap® technology enhances RNA stability and translation efficiency, which are expected to maximize the effectiveness of CRISPR therapeutics.
As the company has recently received a growing number of inquiries from clients regarding gRNA production, ST Pharm plans to complete the construction of dedicated gRNA manufacturing facilities in the third quarter of this year, and to provide a broad range of services to its partners.
A company official stated,
“This event is a meaningful opportunity to introduce ST Pharm’s capabilities in CRISPR-based RNA therapeutics to the global market,” adding,
“We will continue to pioneer new markets by offering total solutions that encompass RNA synthesis, delivery, and production.”